- Advertisement -
The U.S. Food and Drug Administration has approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia (SAA).
…
The U.S. Food and Drug Administration has approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia (SAA).
…